Dyadic International (DYAI)
NASDAQ:DYAI
Want to see DYAI full AI Analyst Report?
DYAI Stock Chart & Stats
$0.93
-$0.19(-9.79%)
At close: 4:00 PM EST
$0.93
-$0.19(-9.79%)
Day’s Range― - ―
52-Week Range$0.65 - $1.35
Previous CloseN/A
Volume131.09K
Average Volume (3M)396.96K
Market Cap
$26.88M
Enterprise Value$26.86M
Total Cash (Recent Filing)$6.52M
Total Debt (Recent Filing)$5.05M
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Aug 12, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding36,438,700
10 Day Avg. Volume144,364
30 Day Avg. Volume396,964
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)24.88
Price to Sales (P/S)24.89
P/FCF Ratio-5.38
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue9.03
Enterprise Value/Gross Profit28.89
Enterprise Value/Ebitda-3.87
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.1
Revenue Forecast (FY)$6.77M
Bulls Say, Bears Say
Bulls Say
Platform Clinical ValidationCompleted Phase I human and nonhuman primate monoclonal antibody studies materially reduce technical and clinical execution risk for the C1 platform. This validation supports partner confidence, eases regulatory conversations, and increases likelihood of licensing, milestones and royalty streams over the next 2–6 months and beyond.
Diversified Revenue Pathways & PartnershipsA multi-path commercial model—product sales, OEM distribution, licensing, profit-share and milestone payments—reduces single-product exposure and capital intensity. Durable partnerships and distribution agreements can accelerate market access while preserving cash, supporting sustainable revenue growth as commercialization progresses.
Revenue And Gross-margin RecoveryMaterial TTM revenue growth and a sharp gross margin rebound indicate improving unit economics and better mix toward higher-margin activities. If sustained, this structural improvement supports scaling without proportional cost increases and enhances prospects for moving toward break-even as product and partner-derived sales expand.
Bears Say
Deteriorated Balance SheetNegative equity and rising debt materially weaken financial flexibility and increase refinancing risk. Over 2–6 months this constrains the firm's ability to fund operations or pursue opportunities without dilutive financing or costly debt, elevating execution risk if commercial receipts lag projections.
Persistent Negative Operating Cash FlowContinued negative operating cash flow requires external financing unless product revenues scale quickly. Cash burn, while improved, still forces management to prioritize runway and may necessitate dilution, grant dependence or partnership monetization, limiting strategic optionality over the coming quarters.
Revenue Dependent On Grants, Milestones And PartnersA large portion of current revenue is contingent on grants, reimbursements and milestone recognition rather than sustained product sales. This partner- and milestone-dependent profile creates timing and predictability risk, and reliance on third-party manufacturing/distribution reduces control over margins and execution pacing.
Dyadic International News
DYAI FAQ
What was Dyadic International’s price range in the past 12 months?
Dyadic International lowest stock price was $0.65 and its highest was $1.35 in the past 12 months.
What is Dyadic International’s market cap?
Dyadic International’s market cap is $26.88M.
When is Dyadic International’s upcoming earnings report date?
Dyadic International’s upcoming earnings report date is Aug 12, 2026 which is in 82 days.
How were Dyadic International’s earnings last quarter?
Dyadic International released its earnings results on May 13, 2026. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of -$0.04 by -$0.01.
Is Dyadic International overvalued?
According to Wall Street analysts Dyadic International’s price is currently Overvalued.
Does Dyadic International pay dividends?
Dyadic International does not currently pay dividends.
What is Dyadic International’s EPS estimate?
Dyadic International’s EPS estimate is -0.04.
How many shares outstanding does Dyadic International have?
Dyadic International has 36,438,700 shares outstanding.
What happened to Dyadic International’s price movement after its last earnings report?
Dyadic International reported an EPS of -$0.05 in its last earnings report, missing expectations of -$0.04. Following the earnings report the stock price went down -2.817%.
Which hedge fund is a major shareholder of Dyadic International?
Currently, no hedge funds are holding shares in DYAI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Dyadic International
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
DYAI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated clear operational and commercial progress: strong YoY revenue growth (182%), multiple product launches and shipments, expanded distribution and partner-funded biopharma validation (Gates and CEPI grants), and platform de-risking via Phase I and preclinical data. At the same time, the company remains early-stage with modest absolute revenues, rising cost of revenue (+~166%) and increased G&A (+10%), continued net losses, dependence on partner execution, and a cash runway that, while adequate into Q2 2027, may require future financing if product revenues do not scale. Overall, the tone is constructive and progress-focused but still highlights execution and scale risks typical of a company transitioning toward commercialization.View all DYAI earnings summariesDYAI Stock 12 Month Forecast
Average Price Target
―Technical Analysis
―
Collplant Holdings
―
Reviva Pharmaceuticals Holdings
―
―
Rani Therapeutics Holdings
―
Ownership Overview
16.31% Insiders
2.81% Mutual Funds
7.24% Other Institutional Investors
70.89% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---